Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches

Drugs

Volumn 54, Issue 5, 1997, Pages 657-678

  Alexander, Barbara D ^a   Perfect, John R ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; ANTIFUNGAL AGENT; ENZYME; ERGOSTEROL; FLUCYTOSINE; FLUOROPYRIMIDINE DERIVATIVE; POLYENE; PYRROLE; THIOCARBAMIC ACID DERIVATIVE;

BIOSYNTHESIS; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOMODULATION; MYCOSIS; PERMEABILITY; PRESCRIPTION; PROPHYLAXIS; REVIEW;

FUNGI;

EID: 0030722130     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754050-00002     Document Type: Review

References (138)

1. Donowitz GR, Mandell GL. Drug therapy: beta-lactum antibiotics. N Engl J Med 1988; 318: 419-26
2. Moherg CL. René Dubos: a harbinger of microbial resistance to antibiotics. Mierobial Drug Resist 1996; 2: 287-97
3. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS [review]. J Acquired Immun Defic Syndr 1992; 5 Suppl. I; 529-32
4. Nugier F, Colin JN, Aymand M. et al. Occurrence and characterization of ucyelovir-resistant herpes simplex virus isolates; report on a two-year sensitivity screening survey. J Med Virol 1992;36; 1-12
5. Kozal MJ, Shafer RW, Winters MA, el al. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long term zidovudine recipients. J Infect Dis 1993; 167: 526-32
6. de Ronde A, de Rooj ER, Coutinho RA, et al. Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam. Nederlands Tijdschr Geneeskd 1996; 140: 932-4
7. Holida MD, Trigg ME, Rumelhart SL, et al. Cytomegalovirus encephalitis resistant to anti-cytomegalovirus therapy [letter]. AIDS 1995; 5: 531-2
8. Dieterich DT, Poles MA, Dicker M. et al. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 1993; 88: 542-8
9. Emini EA, Graham DJ, Gotlib L, et al. HIV and multidrug resistance. Nature 1993; 364: 679
10. Kanj SS, Welly-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine 1996; 75: 142-56
11. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-88
12. St Georgiev V. Fungal infections and the search for novel antifungal agents. Ann NY Acad Sci 1988; 544: 1-3
13. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837-42
14. Laguna F, Rodriguez-Tudela JC, Martinez-Suarez JV. Patterns of fluconazole susceptibility in isolates for human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997; 24: 124-30
15. Duong TA. Infection due to Penicillium marneffti, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23: 125-30
16. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Amimierob Agents Chemother 1995; 39: 1-8
17. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, ilraconawle, and Candida infections. Clin Infect Dis 1997; 24: 235-47
18. Elias S, Cox GM, Meyer W, et al. Use of molecular techniques to evaluate fungal virulence and antifungal resistance in experimental cryptococcal meningitis [abstract] 35th Interscience Conference on Antimicrobial Agents; 1995 Sep 17-20: San Francisco, B68
19. Vanden Bossche H, Marichal P. Odds FC, et al. Characterization of an azole-resistant Candida glahrata isolate. Antimicrob Agents Chemother 1992; 36: 2602-10
20. Nolle FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemolhcr 1997: 41: 196-9
21. Iwata K, Yamashita T, Ohsumi M, et al. Comparative morphological und biological studies on itraconazole- and ketoconuzole-resistant mutants of Cryptococcun neoformann. J Med Vet Mycol 1990; 28: 77-90
22. Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob Agents Chemother 1986; 29: 579-83
23. Bodenhoff J. Development of strains of Cryptococcus neoformans resistant to nystatin, amphotericin B. trichomyein, und polymyxin B. Acta Pathol Microbiol Scand 1968; 73: 572-82
24. Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. J Med Vet Mycol 1984; 22: 53-63
25. Athar MA, Winner HI. The development of resistance by Candida species to polyene antibiotics in vitro. J Med Microbiol 1971; 4: 505-17
26. Horsburgh CR, Kirkpatrick CH. Longterm therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74: 23-9
27. Becker JM, Henry LK, Jiang W, et al. Reduced virulence of Candida albicans mutants in multidrug resistance. Infect Immun 1995; 63: 4515-8
28. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi. Current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-95
29. National Committee for Clinical Laboratory Standards, editors. Reference methods for broth dilution antifungal susceptibil- ity testing for yeasts: tentative standard M27-T. Villanova: National Committee For Clinical Laboratory Standards. 1995
30. Espinel-lngroff A, Kish JrCW, Kcrkering TM, et al. Collaborative comparison of both macrodilution and microdilution antifungal susceptibility test. J Clin Microbiol 1992; 31: 3138-15
31. Galgiani JN. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother 1993; 37: 2517-21
32. Anaissic Ej, Kauyotakis NC, Huehem R, et al. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170: 384-9
33. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 1994; 20: 17-24
34. Velez J, Allendoerfer R, Luther M, et al. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptocnccal meningitis. J Infect Dis 1993; 168: 508-10
35. Walsh TJ, Torres R, Gonzalez LE, et al. Correlation between in vitro and in vivo antifungal activity in a newly developed rabbit model of fluconazole-resistant oropharyngeal and esophagcal candidiasis [abstract no. A64]. 33th Interscience Conference of Antimicrobial Agents: 1995 Sep 17-20: San Francisco
36. Cameron ML, Schell WA, Bruch S, et al. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type I. Antimicrob Agents Chemother 1993; 37: 2449-53
37. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin Infeet Dis 1994; 18: 240-2
38. Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24: 28-34
39. Revanker SG, Kirkpatrick WR, McAtee RK, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174: 821-7
40. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphoteriein B and review of the literature. Clin Infccl Dis 1996; 23: 964-72
41. Sangeorzan JA, Bradley SF, He X, et al. Epidcmiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment and emergence of fluconazole resistance. Am J Med 1994; 97: 339-46
42. Johnson EM, Wamock DW, Luker J, et al. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103-14
43. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19: 684-6
44. He X, Tiballi RN, Zarins LT, et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-7
45. Rodriquez-Tudela JL, Martinez-Suarez JV, Dronda F, et al. Correlation of in vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995; 35: 793-804
46. Sangvireti A, Carmichael JK, Campbell K. Fluconaznle-resislunt Candida albicans after long-term suppressive therapy. Arch Intern Mod 1993; 153: 1122-4
47. Truillet N, Durussel C, Bille J, et al. Correlation between in vitro susceptibility of Candida albicans and flucnazole-resistant oropharyngeal Candidias in HIV-infected patients, Eur J Clin Microbiol Infect Dis 1993; 12: 911-5
48. Rhunke MA, Eigler A, Tennagen I, et al. Emergence of fluconazole resistant strains of Candida albicans in patients e with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-8
49. Maenza JR, Kercily JC, Moore RD, el al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219-25
50. Xiaogang HE, Tiballi RN, Zarins LT, et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-7
51. Espinel-lngroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314-9
52. Walsh TJ, Newman KR, Moody M, et al. Trichosporosis in patients with neoplastic disease. Medicine 1986; 65: 268-79
53. Walsh TJ, Melcher G, Rinaldi M, et al. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J Clin Microhiol 1990; 28: 1616-22
54. Lutwick LI, Golgiani JN, Johnson RH, et al. Visceral fungal infections due to Petriellidium boydii: in vitro drug studies. Am J Med 1976; 61: 632-40
55. Powderly WG, Kobayashi GS, Herig GP, et al. Amphotericin z B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84: 826-32
56. Guinct R, Chanas J, Goullier A, et al. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol 1983; 18: 443-4
57. Dick JD, Rosengard BR, Merz WG, et al. Fatal disseminated candidiasis due to amphotericin B resistant Candida quilliermondii Ann Intern Med 1985; 102: 67-8
58. Pappagianis D, Collins MS, Hector R, et al. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 1979; 16: 123-6
59. Safe LM, Sale SH, Suhden RE, et al. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei and Candida tropicalis. Can J Microbiol 1977; 23: 398-401
60. Drutz DJ, Lehrer RI, Development of ampholericin B resistant Candida tropicalis in a patient with defective leukocyte function. Am J Mcd Sei 1978; 276: 77-92
61. Woods RA, Bard M, Jackson IE, et al. Resistance in polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with ampholericin B resistant funguria. J Infect Dis 1974; 129: 53-8
62. Drew RH, Perfect JR, Flucytosine. In: Merigen YU, editor. Antimicrob Agents Chemother. In press
63. Stiller RL, Bennett JE, Scholer HJ, et al. Correlation of in vitro susceptibility lest results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis 1983; 147: 1070-7
64. Bennett JE, Flucytosine. Ann Intern Med 1977; 86: 319-22
65. Polack A, Scholer HJ. Method of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975; 21: 113-30
66. Block ER, Jennings AE, Bennelt JE. 5-Fluorocytosine resistance in Cryptococcus neofomans. Antimicrob Agents Chemother 1973; 3: 649-56
67. Whelan WL. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol 1987; 15: 45-56
68. Bennelt JE, Dismukes W, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-31
69. Millon L, Manteaux A, Reboux G, et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency viruspositive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115-8
70. Bart-Delabesse EP, Boiron P, Carliotti A, et al. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993; 31: 2933-7
71. White TC, Pfaller MA, Rinaldi MG, et al. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis 1997; 3: 5102-9
72. Winganl JR, Merz WG, Rinaldi MG, et al. Increase in Candida kruseii infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7
73. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulnpsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-9
74. Alangaden G, Chandrasekar PH, Bailey E, et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation: the bone marrow transplantation team. Bone Marrow Transplant 1994; 14: 919-24
75. Hoppe JE, Klingebiel T, Nielhammen D. Selection of Candida glahrata in pediatric bone marrow transplant recipients receiving fluconazole. Pediatr Hematol Oncol 1994; 11: 207-10
76. Kunova A, Trupl J, Spanik S, et al. Candida glabrata. Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole. Chemotherapy 1995; 41: 39-44
77. Bennett JE, Antimicrobial agents: antifungal agents. In Gilman AG, Rail TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: Pergamon. 1990; 1165-81
78. Georgeopapadakou NH, Walsh TH. Antifungal agents: chemotherapeutic targets and immunologic targets. Antimicrob Agents Chemother 1996; 40: 279-91
79. Gallis HA, Drew RH, Pickaid WW, Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-29
80. Vanden Bossche H. Anti-candida drugs: the biochemical basis for their activity. Crit Rev Microbiol 1987; 15: 57-72
81. 7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 1994; 122: 39-42
82. Joseph-Home T, Hollomon D, Loeffler RS, et al. Cross-resistance to polyene and azole drugs in Cryptococcua neoformans. Antimicrob Agents Chemother 1995; 39: 1526-9
83. Sugar AM, Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39: 1907-12
84. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-18
85. Normark S, Schonebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother 1972; 25: 114-21
86. Schonebeck J, Ansehn S, 5-fluorocytosine resistance in Candida spp. and Torulopsis glabrata. Sahouraudia 1973; 11: 10-20
87. Stiller RL, Bennett JE, Scholer HJ, et al. Susceptibility to 5fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrnb Agents Chemother 1982; 22: 482-7
88. Defever KS, Whelan WL, Rogers AL, et al. Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates. Antimicrob Agents Chemother 1982; 22: 810-5
89. Whelan WL. The genetics of medically important fungi. Crit Rev Microbiol 1987; 14: 99-170
90. Jund R, Lacroule F, Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisme. J Bacteriol 1970; 102:607-15
91. Kerridge D, Whelan WL. The polyene macrolide antibiotics and SPC: molecular actions and interactions. In: Trinci APJ, Rylely JF, editors. Mode of action of antifungal agents. Cambridge: Cambridge University Press, 1984: 343-75
92. Hoeprich PO, Ingraham JL, Klecker E, et al. Development of resistance to 5-fluorocytosin in Candida paropsilosis during therapy. J Infect Dis 1974; 130: 112-8
93. Vanden Bossche H, Mariettal P, Le Jeune L, et al. Effects of itraconazole on cytochrome P-450-dependent sterol 14αdemethylation and reduction of 3-ketosteroids. Antimicrob Agents Chemother 1993; 37: 2101-5
94. Holt RJ, Topical pharmacology of imidazole antifungals. J Cutan Pathol 1976; 3(1): 45-59
95. Perfect JR, Savani DV, Durack DT, Uptake of itraconazole by alveolar macrophages. Antimicrob Agents Chemother 1993; 37: 903-4
96. Watson PP, Rose ME, Ellis SW, et al. Defective sterol C5-6 desaluration and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 1989; 164: 1170-5
97. White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol demethylase in Candida albicans. Antimicrob Agents Chemother 1997; 41: 1488-94
98. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86
99. Sanglard D, Ischer F, Monod M, et al. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-5
100. White TC. Increased mRNA of ERG16, CDR, and MDRI correlate with increases in azole resistance in Candida albicans isolates from an HIV-infected patient. Antimicrob Agents Chemother 1997; 41: 1482-7
101. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J Med Vet Mycol 1987; 25: 29-37
102. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition of azole-sensitive and azote-resistant strains of Candida albicans. J Gen Microbiol 1986; 132: 2421-31
103. Venkateswarlu K, Denning DW, Manning NJ, et al. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 1996; 40: 2445-6
104. Albertson CD, Masakazu N, Cannon RD. et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835-41
105. Prasad R, Dewergifosse PA, Goffcau A, et al. Molecular cloning and characterization of a novel gene of Candida albhicans. CDRI, conferring multiple resistance to drugs and anlifungals. Curr Genet 1995; 27: 320-9
106. Clark FS, Parkinson T, Hitchcock CA, et al. Correlation between rhodaminc 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419-23
107. Ambudkar SV, Lelong IH, Zhang CD. Partial purification and reconstitution of the human MDR pump: characterization of the drug stimulatable ATP hydrolysis. Proc: Natl Acad Sci USA 1992; 89: 8472-6
108. Cornwell MM, Tsuro T, Gottesman MM, et al. ATP-hinding properties of P-glycoprotein from multidrug resistant KB cells. FASEB J 1987; 1: 51-4
109. Hamada H, Tsuruo T. Purification of the 170-to 180-kilodalton membrane glycoproitein associated with multidrug resistance. J Biol Chem 1988; 263: 1454-8
110. Fling ME, Kopf J, Tamarkin A, et al. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318-25
111. Balzi E, Goffeau A. Genetics and biochemistry of yeast multidrug resistance. Biochim Biophys Acta 1994; 1187: 152-62
112. Ben-Yaacov R, Knoller S, Caldwell GA, Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrob Agents Chemother 1994; 38:648-52
113. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696-9
114. Johnson EM. Richardson MD, Warnock DW. In vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother 1984; 13: 547-58
115. Smith KJ, Warnock DW, Kennedy CT, et al. Azole resistance in Candida albicans. J Med Vet Mycol 1986; 24: 133-44
116. Barchiesi F, Colombo AL, McGough DA, et al. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1530-3
117. Ruhnke MA, Eigler A, Engelmann E, et al. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 1994; 22: 132-6
118. Casadevall A, Spitzer ED, Webb D, et al. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicroh Agents Chemother 1993; 37: 1383-6
119. Bodey GP, Anaissie E, Gutterman J, et al. Role of granulocytemacrophage colony stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705-7
120. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinanl human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907-13
121. Rex JH, Bennett JE, Gallin Jl, et al. In vivo Interferon gamma therapy augments the in vivo ability of chronic granulomatous disease neutrophils to damage Aspergilliu hyphae. J Infect Dis 1991; 163: 849-52
122. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in presentation and treatment of serious infections in inununocompromised hosts. Clin Infect Dis 1992; 15: 508-23
123. Meyers J, Nemunaitis J, Shannon-Dorcy K. et al. Long-term followup of patients with invasive fungal disease who received adjunctive therapy with recomhinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422-7
124. Conzalez. CE, Couried DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997; 241: 192-6
125. Nemunaitis J. A comparative review of colony-stimulating factors. Drugs 1997; 54: 719-39
126. Mukherjee J, Zuckier LS, Scharff MD, et al. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucunmoxylomannan alone and in comhinalion with amphotericin B. Anlimicrob Agents Chemother 1994; 38: 580-7
127. Gordon MA, Casadevall A, Serum therapy of cryptococcal meningitis. Clin Infect Dis 1995; 21: 1477-9
128. Heald AE, Cox GM, Schell WA, et al. Oropharyngeul yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996; 10: 263-8
129. Perfect JR, Antifungal prophylaxis: to prevent or not. Am J Med 1993; 94: 233-4
130. Hiemenz JW, Walsh TJ. Lipid formulations of amphoteriein B: recent progress and future directions. Clin Infect Dis 1996; 22: 133-44
131. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-5
132. Perfect JR, Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemolher 1996; 40: 1577-83
133. Perfect JR, Cox GM, Dodge RK, et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus nepformans. Antimicrob Agents Chemother 1996; 40: 1910-3
134. Espinel-lngroff A. Evaluation of the in vitro activity of the new triazole voriconazole against opportunistic filamentous fungi (abstract). 36th International Conference of Antimicrobial Agents Chemotherapy (ICAAC): 1996 Sep 15-18: New Orleans: American Society for Microbiology. F84
135. Stevens DA. Martinez M, Devine MJ. Antifungal activity of LY303366. an echinocandin beta glucan synthase inhibitor (abstract). 36th International Conference of Antimicrobial Agents Chemotherapy (ICAAC): 1996 Sep 15-18: New Orleans. F46
136. Del Pocta M, Schell WA, Perfect JR. In vitro antifungal activity of L-743,872 against a variety of moulds. Antimicrob Agents Chcmother. In press
137. Hector RK Schalter K. Positive interaction of nikkomyein and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1992; 36. 1284-9
138. Oki T, Konishi M, Tomatsu K, et al. Pradimicins. a novel class of potenl antifungal antibiotics. J Antibiol 1988; 41: 1701-4